Connor, Clark & Lunn Investment Management (CC&L)
JANX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Janux Therapeutics JANX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
+119,376
New +$1.64M ﹤0.01% 1014
2024
Q2 		– Sell
-6,892
Closed -$259K – 1528
2024
Q1 		$259K Sell
6,892
-5,924
-46% -$129K ﹤0.01% 1320
2023
Q4 		$138K Buy
+12,816
New +$111K ﹤0.01% 1298

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s JANX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Janux Therapeutics (JANX) in Q1 2026: 119,376 shares worth $1.66M. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in JANX as recently as Q1 2024.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in JANX in Q4 2023 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 119,376 shares of Janux Therapeutics worth $1.66M as of Q1 2026.
  • Janux Therapeutics was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
  • Janux Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1014 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Janux Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.